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A B S T R A C T
Purpose: To determine factors associated with lack of response to valproic acid (VPA) in juvenile
myoclonic epilepsy (JME).
Method: Retrospective analysis of clinical and EEG data of 201 patients with JME who had at least 3 years
follow up was performed. Psychiatric evaluation was performed using ICD-10 by structured clinical
interview. Patients were divided into two groups: VPA responders (seizure free for 2 or more years) and
those with lack of response to VPA. Effect size for non-response and correlations for variables
signiﬁcantly different between the groups was performed, the ﬁndings were conﬁrmed by ROC curves.
Results: The mean duration of follow up was 7.75 (range 3–12) years; 55.2% were males. Focal
semiologic features were noted is 16%. EEG was abnormal in 67%; focal EEG abnormalities were noted in
32.8%. Coexisting psychiatric disorders (PDs) were found in 33.3%. Lack of response to VPA was noted in
19%. Diagnosis of PDs and focal EEG abnormalities signiﬁcantly increased the risk of VPA non-
responsiveness by 5.54 (95% CI of 2.60–11.80; p < 0.0001) and 3.01 times respectively (95% CI of 1.40–
6.47; p < 0.008). Diagnosis of PDs showed signiﬁcant correlation (r = 0.332; p < 0.0001) and association
(AUC 0.700; p < 0.0001) with lack of response to VPA. Though focal EEG abnormalities increased the
chances, it did not correlate with lack of response to VPA.
Conclusion: Lack of response to VPA was noted 19% of patients with JME. Coexisting PDs showed
signiﬁcant correlation and association with lack of response to VPA.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Juvenile myoclonic epilepsy (JME) is the most common
idiopathic generalized epilepsy (IGE) in adults, characterized by
myoclonic jerks (MJ) on awakening, generalized tonic clonic
seizures (GTCS) and typical absences in about one third of
patients.1–4 JME is equally prevalent amongst both the sexes
and accounts for 10% of all epilepsies and up to 26% of all IGEs.3 It is
an age-dependent syndrome; absences, MJ and GTCS show a
characteristic age related onset.5–7 However 10% never develop
GTCS. Genetically JME is determined by ﬁve Mendelian genes.8
The EEG is usually abnormal in untreated patients.3,7 Paroxys-
mal abnormalities consist of generalized spike, polyspike and slow* Corresponding author at: Department of Neurology, Krishna Institute of
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activity with interspersed small spikes (27%). Most of the
discharges last for 1–3 (range 1–20) s. Focal clinical and EEG
features were reported in up to 30% of patients with JME.9,10
Photosensitivity is age dependent and photo paroxysmal dis-
charges were elicited in up to one third of patients. Although
routine brain imaging is normal, abnormalities involving mesio-
frontal cortical structures on magnetic resonance imaging (MRI)
have been reported in some patients.11
JME is considered to be a relatively benign form of IGE. Valproic
acid (VPA) is the ﬁrst drug of choice in JME and response to
treatment is good to excellent; VPA effectively controls seizures in
up to 80% of the patients with JME, but spontaneous remission is
extremely rare.12 Amongst patients with seizure relapse, discon-
tinuation of medication is common reason, even after many years
of seizure control. Fortunately, remission can be maintained for
several years with appropriate medications.13 Lamotrigine is a
useful alternative in patients with JME who are intolerant to or
develop side effects with VPA. In resistant cases the addition ofserved.
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monotherapy.14 On the contrary, VPA may not be the choice of
drug in few patients due to reported side effects such as tremor,
weight gain, alopecia and the risk of teratogenicity.15 Topiramate
and levetiracetam were shown to be well tolerated and effective in
some patients with resistant JME or those intolerant to VPA.16–18
True drug resistance in JME has been reported and ranges from
15 to 30%.10,19–22
Delayed diagnosis of epilepsy, inappropriate AED treatment, high
percentage of asymmetric (or) focal discharges on scalp EEG were
factors responsible for intractable JME. Whilst the combined
occurrence of all three seizure types and coexisting psychiatric
disorders (PDs) were found to be risk factors associated with drug
resistance in JME,10,19–21 there is paucity of literature conﬁrming to
what extent these factors increase the risk of lack of response, both
as single entity or in combination with other clinical characteristics.
If these factors were associated with lack of response to VPA in
patients with JME, this may help to identify non-responders early
and prescribe appropriate intervention. In the present study we
analyse the factors associated with lack of response to VPA in
patients with JME.
2. Materials and methods
A retrospective analysis of clinical and EEG data (January 2000
to January 2011) of all the patients with a diagnosis of JME, who
were part of a larger epilepsy registry, and who were followed up
for least 3 years was performed. The registry was maintained by
the Neurologist (SJ) who is part of the comprehensive epilepsy care
programme. The diagnosis and follow up of JME was made by SJ
.The diagnosis of JME was based on International Classiﬁcation of
Epilepsies.1 The inclusion criteria were: (1) Unequivocal clinical
(historical) evidence of MJ predominantly on awakening with (or)
without GTCS and (or) absence seizures. (2) No evidence of
neurological (or) intellectual deﬁcit. (3) Abnormal EEG in
untreated patients with generalized spike and (or) multiple spike
wave discharges; focal (or) background abnormalities were
acceptable if other clinical and EEG criteria were strictly justiﬁed
and a normal EEG in treated patients. (3) Those who received VPA
as the ﬁrst AED with good compliance; whereas, the exclusion
criteria were: (1) pseudoresistant cases of JME due to inadequate
lifestyle, poor AED compliance, or those who were never tried on
VPA. (2) Patients with evidence of neurological (or) intellectual
deﬁcit and those with evidence of myoclonic jerks secondary to
brain hypoxia, metabolic disease and degenerative diseases. (3)
Non availability of at least one EEG record for review.
Data of patients who satisﬁed all the inclusion criteria for
diagnosis of JME was obtained with uniform protocol for data
collection. The study was approved by the institutional ethics
committee. The data collected included, demographic data,
semiology, type of seizures, time of occurrence of GTCS and MJ,
precipitating factors, past history of febrile seizures, family history
of epilepsy, imaging (CT/MRI) of brain (if performed), AED
treatment details.
2.1. Psychiatric evaluation
All subjects were evaluated by a clinical psychologist, using
International classiﬁcation of psychiatric disorders (ICD-10) by a
structured clinical interview method. Each patient can have more
than one psychiatric diagnosis in Axis I disorders.
2.2. EEG
A 21 channel EEG recording was done according to internation-
al 10–20 system using Nicolet VEEG machine. Sleep deprived EEG(with 4 h sleep in the preceding 24 h) for 40 min (20 min sleep
followed by 20 min awake or 40 min awake EEG) was performed
including 3 min of hyperventilation (HV) and photic stimulation
from 1 to 30 ﬂashes/s without modifying the present AEDs. Filters
used were 70 Hz and 0.5 Hz. The EEGs and the previous EEGs when
available were read independently by two consultant neurolo-
gists without the knowledge of clinical history and ﬁndings with
agreement were reported. The EEGs were always reviewed in
more than one montage. EEG was classiﬁed as ‘abnormal’ only
when deﬁnite bilaterally symmetrical, generalized spike-wave
(or) polyspike and slow wave discharges (including photo
paroxysmal response) were seen. EEGs were carefully evaluated
for any focal abnormalities. EEG asymmetries were deﬁned as
asymmetry in the amplitude of generalized discharges of >50% or
focal onset preceding the generalized discharges. Independent
focal EEG abnormalities were deﬁned as occurrence of indepen-
dent focal spike/sharp wave discharges, focal slowing or phase
reversals in the abnormal EEGs having generalized epileptiform
discharges.
2.3. Treatment
All the patients received either VPA or lamotrigine or
levetiracetam as the ﬁrst line AED as per routine practice in
our centre. The reasons for using lamotrigine or levetiracetam as
ﬁrst line AED included: VPA related adverse effects, women with
child bearing potential. Topiramate was used in JME patients
with associated migraine. The patients who received AED other
than VPA were excluded from the study. None of our patients
were on carbamazepine, phenytoin or phenobarbitone. VPA
resistance was deﬁned as persistent seizures (GTCS, absence
seizures, MJ) despite use of maximum tolerated dose of VPA for
the treatment of JME and adequate lifestyle.21 Serum VPA levels
were measured in 52 patients (including all with lack of
response to VPA). The patients were divided into two groups –
responders to VPA (seizure free for two or more years) and those
with lack of response to VPA (having moderate to poor seizure
control despite optimal serum VPA level).
2.4. Statistical analysis
After conﬁrming the homogeneity of the data, the differences
between patients with response to VPA and those with lack of
response were analysed using Chi square test for categorical
variables and student un-paired t test for continuous variables. All
the factors that were signiﬁcantly different between the groups
were tested for association with remission using spearman
correlation. The effect size on lack of response to VPA was
calculated for EEG abnormalities and PDs. Moreover, the sensitivity
and speciﬁcity of factors associated with remission was analysed
using ROC curves. All the statistical analysis was performed using
Statistical Package for Social Sciences software version 17.0, IBM
Computers, Illianos, Chicago, USA. A p < 0.05 was considered
signiﬁcant.
3. Results
There were a total of 269 patients with diagnosis of JME
and accounted for 11.2% of the patients of the epilepsy registry.
Of these 68 patients were excluded; the reasons being
poor compliance and/or poor lifestyle (sleep deprivation and
regular alcohol intake) in 19, inadequate dose of VPA in 6,
AED used was lamotrigine in 16, levetiracetam in 22,
and topiramate in 5. Finally 201 patients were included for
analysis.
Table 1
Baseline characteristics of patients with juvenile myoclonic
epilepsy.
Parameter Number (%)
Sex
Males 111(55.2)
Females 90(44.8%)
Mean age of onset
MJ 14.9 years
GTCS 15.4 years
Absences 8.64 years
Seizure type
MJ only 9(4.47)
GTCS + MJ 150(74.6)
Absences + GTCS + MJ 42(20.9)
Myoclonic jerks
Random occurrence 48(23.9)
On awakening 153(76)
Focal features in semiology 32(15.9)
Precipitating factors
Sleep deprivation 126(63)
Fatigue and exercise 95(47)
Sudden awakening 56 (28)
Well controlled epilepsy 163(81)
Valproic acid resistant epilepsy 38(19)
Positive family history of epilepsy 74(36.8)
Febrile seizures 23(11.4)
EEG features
Abnormal EEG 134(66.7)
Positive PPR 26(19.4)
Focal EEG abnormalities 44(32.8)
Psychiatric disorders 67(33.3)
Anxiety disorders 33(49.3)
Depressive disorder 26(38.8)
Mixed anxiety with depression 7(10.5)
Schizophrenia 1(1.5%)
MJ, myoclonic jerks; GTCS, generalized tonic clonic seizures;
EEG, Electroencephalogram; PPR, photoparoxysmal response.
Table 3
Focal EEG abnormalities in patients with juvenile myoclonic epilepsy.
Focal EEG abnormality Number
Asymmetry of spike wave/polyspike wave discharges 28
Asymmetry at onset of generalized epileptiform discharge 24
Independent focal EEG abnormalities (spike/sharp waves) 21
Focal slowing 4
Asymmetric photoparoxysmal response 7
EEG, electroencephalogram.
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Amongst the 201 patients, MJ were noted in all 201 patients.
The baseline characteristics of the study population were shown in
Table 1. Focal features in semiology from history like head version,
asymmetric tonic posturing or clonic movements of a limb in GTCS,
asymmetric myoclonic jerks (as described by a relative or the
patient) was noted in 32 patients (15.9%). Of the 201 patients who
satisﬁed inclusion criteria, 163 (81%) of the patients had good
response to VPA and were in remission, where as 38 (19%) patients
had lack of response to VPA. The mean duration of follow up was
7.2 (range 3–12) years. The average age of the study population
was 23  9 years (Table 1), however, the average age of the non-
responder group was higher (25  9 vs. 22  9; p = 0.053). There was
no signiﬁcant difference between the groups for gender distribution
(Male – 54.6% vs. 57.9%; p = 0.428), age of onset of epilepsy (<20
years, 84.5% vs.86.8%; p = 0.80), percentage of patients with duration
of epilepsy for greater than two years (83.4% vs. 89.5%; p = 0.256),Table 2
Clinical and demographic differences between responders and non-responders to valp
Variable Responders to VPA (n-163)
Age (years) 22  9 
Age of onset 20years (%) 84 
Male (%) 54.6 
Duration of Epilepsy > 2 years (%) 83.4 
All 3 types of seizures (%) 19.6 
Family history of epilepsy (%) 38.7 
Febrile seizures (%) 12.9 
Focal EEG changes (%) 17.8 
Co-existing psychiatric disorders (%) 25.8 
Duration of follow up (months) 85.4  25.6 
p value < 0.05, considered as signiﬁcant difference between groups. EEG, electroencephcombination of all three types of seizures (19.6% vs. 26.3%; p = 0.240),
family history of epilepsy (38.7% vs. 28.9%; p = 0.351) and fraction of
patients with febrile seizures (12.9% vs. 8.7%; p = 0.146). Similarly,
patients in both the groups were followed up for approximately same
period of time (85.4  25.6 vs. 86.4  26.6 months; p = 0.788). Table 2
summarizes the difference between the two groups for all the clinical
and demographic data.
3.2. EEG
The number of EEGs per patient ranged from 1 to 9 (mean 3.2).
At least one abnormal EEG was noted in 134 patients (66.7%). All
the 9 patients with only MJ had abnormal EEG. The PPR was
positive in 26 patients (19.4%). Focal EEG abnormalities were noted
44 patients (32.8%). The various EEG abnormalities were calculated
as a percentage of the 134 patients who had an abnormal EEG, not
of the entire cohort. Table 3 shows various types of focal EEG
abnormalities noted in EEGs with typical generalized epileptiform
discharges. The occurrence of focal EEG abnormalities was
signiﬁcantly higher in VPA non-responders when compared to
VPA responders (39.5% vs. 17.8%; p < 0.001).
3.3. Imaging
CT/MRI brain was available in 99 patients and was normal. All
the patients with lack of response to VPA underwent brain MRI and
it was normal.
3.4. Psychiatric evaluation
Psychiatric evaluation was suggestive of a signiﬁcant psychiat-
ric diagnosis in 67 (33.3%) patients in the entire cohort; 65.8% (25/
38) of patients with lack of response to VPA were diagnosed to have
a PDs, a signiﬁcantly (p < 0.001) higher proportion than the VPA
response group where only 42 out 163 (26.4%) patients were
diagnosed to have PDs. Amongst the 67 patients with psychiatric
diagnosis, anxiety disorders (generalized anxiety disorder (GAD),
obsessive compulsive disorder (OCD) and phobic anxiety disorder)
were more common and noted in 49.3% patients. Depressive
disorder (mild to moderate depression, and dysthymia) was found
in 38.8%; 7 patients had mixed anxiety with depression and
schizophrenia was diagnosed in one (Table 1).roic acid in patients with JME.
 Non-responders to VPA (n-38) p value
25  9 0.053
86.8 0.806
57.9 0.428
89.5 0.256
26.3 0.240
28.9 0.351
8.7 0.146
39.5 <0.001
65.8 0.016
86.4  26.6 0.788
alogram.
Table 4
Odds Ratio to detect lack of response to VPA using EEG abnormalities and
psychiatric disorders (n = 201).
Variables OR 95% CI p value
Focal EEG Abnormality (n = 44) 3.01 1.40–6.47 0.008
Psychiatric diagnosis (n = 67) 5.54 2.60–11.80 <0.0001
Focal EEG abnormality or
psychiatric diagnosis (n = 96)
8.25 3.26–20.84 <0.001
Focal EEG abnormality and
psychiatric diagnosis (n = 15)
5.94 2.00–17.62 0.002
Abbreviations: EEG, electroencephalogram; OR, odds ratio for non-remission; CI,
conﬁdence interval.
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Valproic acid was the ﬁrst line AED used in all the patients; 163
(81%) were in remission. Amongst this group 2 patients with
isolated MJ were off the AEDs for more than 5 years and seizure
free. Thirty eight patients (19%) required more than one AED and
were grouped as JME with lack of response to VPA. Serum VPA level
was within reference range in all the patients with lack of response
to VPA. The other AEDs given in addition to VPA were clobazam,
clonazepam, lamotrigine, levetiracetam, zonisamide and topir-
amate; 28 were on combination therapy with 2 AEDs (7 patients
were seizure free for more than one year) and 10 were on 3 AEDs.
While all the factors that were signiﬁcantly different between the
groups were analysed for association with lack of VPA response,
diagnosis of PDs showed the strongest correlation with lack of
response to VPA (r = 0.332; p < 0.0001). The diagnosis of PDs
signiﬁcantly increased the risk of VPA non-responsiveness by 5.54
times with 95% CI of 2.60–11.80 (p < 0.0001) but the other two
factors that were signiﬁcantly different between the groups namely,
focal EEG abnormalities and the duration of epilepsy did not show
signiﬁcant correlations with lack of response to VPA. However focal
EEG abnormalities were associated with lack of response to VPA by 3
times with 95% CI of 1.40–6.47 (p = 0.008). The relative risk ratio for
lack of response to VPA is summarized in Table 4.Fig. 1. ROC curve for lack of response to VPA and focal EEG abnormalities and
psychiatric disorders.Subsequently patients were divided in to four groups: patients
with PDs alone, focal EEG abnormalities alone, PDs or focal EEG
abnormalities, PDs and focal EEG abnormalities. ROC curves were
plotted for lack of response to VPA for the above mentioned four
groups showed, that diagnosis of PDs was sensitive to lack of
response to VPA with an area under curve of 0.700; p < 0.0001;
furthermore, occurrence of focal EEG abnormalities or PDs had an
area under curve of 0.725; p < 0.0001. On the contrary, presence of
focal EEG abnormalities alone (AUC 0.608; p = 0.04) or presence of
focal EEG abnormalities along with PDs in a combination (AUC
0.584; p = 0.108) were not sensitive to detect lack of response to
VPA. Fig. 1 summarizes the ROC curves of the variable assessed in
the study cohort.
4. Discussion
The current study conducted at a tertiary referral care in South
India, shows an incidence of JME of 11.2%, similar to the prevalence
reported elsewhere in the world.7 Importantly, the current study
has shown that irrespective of other clinical features and/or
investigations; diagnosis of PDs may anticipate lack of response to
VPA.
The present study reﬂects a typical JME population with
characteristics similar to other studies reported previously.7,13,23–
25 The combination of absence seizures with GTCS and MJ was seen
in 20.9% as described before.8,26 On the contrary, incidence of
febrile convulsions in the present study was higher than that
reported by Janz et al. reﬂecting some ethnic variation or
ascertainment bias.25 Family history of epilepsy was noted in
36.8% which was similar to a study from India.27 EEG was abnormal
in 66.7% in the present study, lesser when compared to previous
studies. It could be due to the reason that most of the EEGs were
done when the patients were on AEDs. Focal EEG abnormalities
were seen in 44% which was higher when compared to a study by
Aliberti et al.9
JME is considered to have relatively good seizure outcome. True
resistance to VPA monotherapy is uncommon. Drug resistance in
JME should be considered after excluding the causes of pseudo
resistance which may be due to wrong AED choice, inadequate
lifestyle and poor compliance. Previous studies showed that 70–
80% of JME population was controlled on VPA monotherapy.7,22
Similarly, in the present study 81% of patients responded to VPA
monotherapy. Psychiatric disorders and focal EEG abnormalities
were associated with lack of response to VPA monotherapy.
Gelisse et al., in 2001, in a study of 155 JME patients reported
pseudo resistance in 9.7% and true resistance in 15.5%.21 They
found that the predictors of drug resistance were presence of
psychiatric problems and the combination of all three seizure
types. In recent study prolonged duration of epilepsy, combination
of all three seizure types and epileptiform discharges in baseline
EEG were associated with poor seizure control on VPA mono-
therapy or polytherapy. They also found that compared to seizure-
free patients, those with persistent seizures were of younger age at
epilepsy onset and had higher prevalence of personality dis-
orders.28 The current study, however found that co-existing PDs
were strongly associated with lack of response to VPA in JME
patients. Focal EEG abnormalities though increased the chances,
did not correlate with lack of response to VPA; moreover there was
no correlation between lack of response to VPA and duration of
epilepsy, family history of epilepsy, age at onset and combination
of all three types of seizures. In a long-term follow up study 32.5%
of JME patients continued to have seizures despite multiple AEDs;
the occurrence of GTCS preceded by bilateral MJs and complete
remission of GTCS under AEDs signiﬁcantly increased the chance
for complete seizure freedom.29 It has been reported that patients
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response to VPA monotherapy, similar to the present study.20,30
Patients with JME show focal clinical and EEG features which
should not be misinterpreted as indicative of partial epilepsy. In a
follow up study of 33 patients with JME at Duke epilepsy centre,
30% were VPA resistant; EEG asymmetries were noted in 40% of
VPA resistant group when compared to 10% in VPA sensitive JME
patients.22 They also found that auras, post-ictal confusion and
intellectual deﬁciency were more common in VPA resistant group.
However in another study EEG asymmetries were not associated
with resistance to treatment.31 We followed strict inclusion
criteria and one of them was no evidence of intellectual deﬁcit.
In the present study focal EEG abnormalities increased the chances
but did not correlate with lack of response to VPA. The possible
mechanisms for these focal EEG features include imbalance
between both the cerebral hemispheres, focal cortical pathology
like microdysgenesis and development over time of localized, self-
sustaining hyperexcitability in low-threshold cortical structures
subjected to genetic and environmental factors.32
Association of PDs has been described in 26.5–49% of patients
with JME.33–36 They include anxiety disorders, mood disorders and
personality disorders. We noted PDs in 33.3% with JME. The
prevalence of PDs was 26.5% in patients with JME when evaluated
using DSM IV in a cohort of 170 patients.34 We noted that anxiety
disorders (49.3%) were more frequent than depressive disorders in
JME. In a study from Brazil the prevalence of PDs in JME was 49%.
Anxiety and mood disorders (23% and 19%, respectively) were the
most common and a statistically signiﬁcant association between
anxiety disorders and JME was noted.35 We noted a signiﬁcant
association between PDs and lack of response to VPA. Psychiatric
evaluation and a diagnosis of co-existing PDs may anticipate lack of
response to VPA early in these patients. Coexistence of PDs in JME
has been found to be associated with increased seizure frequency
and poor therapeutic control.21,36 Baykan et al. observed true-
resistant course in 16.7% of JME patients and it was signiﬁcantly
associated with PDs and presence of thyroid disease.37 There are no
studies till date determining the association of combined focal EEG
abnormalities and PDs with drug resistant JME. We found that
presence of focal EEG abnormalities does not add signiﬁcantly
more to presence of PDs alone in estimating the probability of lack
of response to VPA.
4.1. Limitations
Despite the best of the cautions exercised, the following are the
limitations of the study. First, a small sub group of patients did not
receive VPA. Secondly we did not include patients on lamotrigine
and levetiracetam as monotherapy, which are emerging as good
alternatives to VPA especially in women with child bearing
potential. Thirdly we ascertained focal features based on EEG
rather than video EEG recordings. However, the ﬁndings of the
current study are plausible in clinical context where in most of the
demographic data in the current study is in concordance with
existing literature, more over 81% responded to VPA monotherapy,
a number that mirrors ﬁndings reported by previous investigators.
5. Conclusion
Juvenile myoclonic epilepsy is well controlled with VPA. There
is a sub group of patients with JME who lack response to VPA. We
found that PDs are associated with lack of response to VPA.
Psychiatric disorders in JME may anticipate lack of response if they
occur prior to the onset of refractoriness, there by avoid delays in
initiating appropriate drug management in these patients. The
treating physician should be careful in this subset of patientsbefore informing the newly diagnosed JME patients that their
epilepsy has good outcome.
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